Sideroblastic anemia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2] Associate Editor(s)-in-Chief: Nazia Fuad M.D.

Overview

Effective measures for the secondary prevention of sideroblastic anemia include iron chelators, Phlebotomy, regular liver function tests to assess for liver disease. Other measures include regular CBC in patients with MDS, cardiac monitoring, monitoring iron studies , and keeping ferriten level < 500 ng/ml.

Secondary Prevention

Effective measures for the secondary prevention of sideroblastic anemia include:^[1]

Iron chelators
Phlebotomy
Regular liver function tests to assess for liver disease
Regular CBC in patients with MDS myelodysplastic syndrome
Cardiac monitoring
Monitor iron studies , keep ferriten level < 500 ng/ml
Pyridoxine supplementation, 50-100mg a day

References

↑ Ohba R, Furuyama K, Yoshida K, Fujiwara T, Fukuhara N, Onishi Y; et al. (2013). “Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS)”. Ann Hematol. 92 (1): 1–9. doi:10.1007/s00277-012-1564-5. PMC 3536986. PMID 22983749.

Template:WS Template:WH

[pmid22983749-1] Ohba R, Furuyama K, Yoshida K, Fujiwara T, Fukuhara N, Onishi Y; et al. (2013). “Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS)”. Ann Hematol. 92 (1): 1–9. doi:10.1007/s00277-012-1564-5. PMC 3536986. PMID 22983749.

[1]